Matapos ianunsyo ang kanilang "safe" at "effective" antidote, inialok ng Russia sa Pilipinas ang COVID-19 vaccine nito--at positibo naman ang tugon ng nahuli sa mungkahing ito.
Ads
Sa isang press briefing kamakailan, sinabi ni Russian Ambassador Igor Khovaev na layunin nilang magsagawa ng clinical trials at magtayo ng vaccine production hub sa Pilipinas kung aaprubahan ito ng gobyerno.
"We are ready to combine our efforts, we are ready to make the necessary investments with our Filipino partners and we are ready to share our technologies simply because we want to build a robust partnership between our two nations," ani Khovaev.
Pagpapatuloy niya, hindi sila nangangako, kung 'di nagbibigay ng mungkahi base sa kung ano ang alam nila at kung ano na ang kanilang nagawa.
Ads
Sponsored Links
Wika ng opisyal, sa kasalukuyan ay maganda ang itinatakbo ng series of trials na isinasagawa ng grupo ng volunteers sa Russia.
"We don't make promises. We make suggestions based on what we already know and what we have done," aniya. "We already have the vaccine so all necessary bureaucratic procedures in order to get an official administrative approval might be completed until mid-August. The vaccine is effective and safe."
Positibo naman ang tugon ng Department of Foreign Affairs (DFA) sa nasabing proposal.
“The DFA conveys its appreciation for Russia’s willingness to assist the Philippines in its fight against COVID-19, as well as its offer to supply the SARS-COV-2 vaccine developed by N.F. Gamaleya of the Ministry of Health of the Russian Federation,” saad nito sa isang statement.
Narito ang mga dapat mong malaman tungkol sa bakuna na idine-develop ngayon ng Russia:
Bilang bahagi ng emergency grant aid nito sa mga bansang malaki ang problemang kinahaharap ngayon bunsod ng pandemya, nagpadala ang Japan ng Avigan tablets para sa 100 COVID-19 patients sa Pilipinas.
Ads
Ayon statement mula sa Japanese Embassy sa Manila, nakarating na sa Department of Health (DOH) ang Japan-made anti-flu drug na Avigan; kamakailan lamang ay nakapukaw ng interes ng maraming bansa dahil sa potensyal nito na pumigil ng viral replication, kahit pa ang bisa nito kontra sa COVID-19 ay kasalukuyan pang tinitingnan.
“The Government of Japan delivered Avigan tablets for 100 patients to the Philippine Department of Health on August 6, 2020 as part of its emergency grant aid to countries severely affected by COVID-19,” saad ng embahada.
Ads
Sponsored Links
“Japan-made anti-flu drug Avigan has drawn interest from many countries for its potential to prevent viral replication, even as its effectiveness against the novel coronavirus is yet to be established," pagpapatuloy nito.
Avigan: Clinical Research
Bilang tugon sa mga request ng mula sa international community, nakipag-ugnayan ang Japan sa iba't ibang bansa--kabilang na ang Pilipinas--upang mas mapalawak pa ang pananaliksik nito na may kinalaman sa paggamit ng Avigan bilang lunas sa mga nakahahawang sakit.
“In response to the requests received from the international community, Japan has formed close cooperation with several countries, including the Philippines, to expand clinical research on Avigan as treatment for this infectious disease,” saad ng statement.
“Each recipient government has acknowledged of Avigan’s proper usage and prescription in view of its known adverse side effects,” dagdag pa nito.
Umaasa raw ang Japan na makatutulong ang pakikipag-isa nito sa Pilipinas sa layuning makatuklas ng paraan upang mapahinto na ang COVID-19 pandemic.
“Japan hopes that this ongoing cooperation with the Philippines would further contribute to the advancement of clinical research to contain the COVID-19 pandemic,” wika nito.
Isang biotech na kumpanya sa Amerika, ang Moderna ang naglabas ng resulta ng Phase 1 clinical trial ng denedevelop nila na vaccine laban sa Corona Virus 2019 o COVID19. Sa ilang katao na natest na ay may 8 na mga participants ang may lumabas na magandang resulta, at may nakitang neutralizing antibodies sa kanilang katawan. Ibig sabihin, gumagawa mismo ang kanilang katawan ng mga mga anti bodies sa tulong ng vaccine na nilalabanan ang corona virus, at nananatiling safe ang mga naturukan ng vaccine na ito. Sa pag-aaral pa ng Moderna, na ginamitan ng daga o mice, pagkatapos naturukan ng vaccine, napag-alaman na hindi tinatamaan ng corona virus ang daga na may vaccine.
Ads
Ayun pa sa Moderna, sa July mag-uumpisa ang malakihang clinical trial, at maaring sa January to June 2021 ay magiging available na ang vaccine sa market. Narito ang video ng biotech na Moderna na nageexplain ng kanilang ginawang trial, at kung paano sila nakadevelop ng mRNA-1273 in just 42 days.
After two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts seroconverted with binding antibody levels at or above levels seen in convalescent sera
mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants across the 25 µg and 100 µg dose cohorts, reaching or exceeding neutralizing antibody titers generally seen in convalescent sera
mRNA-1273 was generally safe and well-tolerated
mRNA-1273 provided full protection against viral replication in the lungs in a mouse challenge model. Anticipated dose for Phase 3 study between 25 µg and 100 µg; expected to start in July
Ads
Narito naman ang interview sa isa sa mga nabigyan ng vaccine at kasali sa clinical trial na ito.
Sponsored Links
Ayun pa sa kumpanya, naapprove na ng FDA ng USA ang pagsasagawa nila ng pangalawang trial at ang pangatlong trial ngayong July 2020 at magiging available na ito next year. Phase 1 safety and immunogenicity data from the trial being run by the NIH is expected to guide our next steps. Given the pandemic, we have started to work in parallel to responsibly accelerate further development.
The Company is actively preparing for a potential Phase 2 study under its own Investigational New Drug (IND) filing to build on data from the ongoing Phase 1 study being conducted by the NIH. To continue to progress this potential vaccine during the ongoing global public health emergency, Moderna intends to work with the FDA and other government and non-government organizations to be ready for a Phase 2 and any subsequent trials, which are anticipated to include a larger number of subjects and which will seek to generate additional safety and immunogenicity data. Manufacture of the mRNA-1273 material for the potential Phase 2 trial, which could begin in a few months, is underway. Moderna continues to prepare for rapid acceleration of its manufacturing capabilities that could allow for the future manufacture of millions of doses should mRNA-1273 prove to be safe and effective.
Our goal is to generate data that will demonstrate the safety and effectiveness of mRNA-1273 against infection caused by SARS-CoV-2.
"Moderna has already started to prepare for rapid acceleration of its manufacturing capabilities that could allow for the future manufacture of millions of doses should mRNA-1273 prove to be safe and of expected benefit. We are working around-the-clock to make sure a vaccine is available as quickly and as broadly as possible. We will continue to work together, with government, industry and other third parties to enable the best chance for success." CNN REPORTS
Sponsored Links
U.S. researchers administered the first shot to the first person in a test of an experimental coronavirus vaccine. With a careful jab on a healthy volunteer's arm, scientists at the Kaiser Permanente Washington Research Institute began an anxiously-awaited first-stage study of a potential COVID-19 vaccine. Even if the research goes well, a vaccine wouldn't be available for widely use for 12-18 months, according to the U.S. National Institutes of Health. The trial vaccine, code-named mRNA-1273, was developed by the NIH and Massachusetts-based biotechnology company Moderna Inc. There are no chance participants can get infected from the shots because they don't contain the coronavirus itself. Kaiser Permanente screened dozens of people, looking for those who have no chronic health problems and aren't currently sick. Participants are paid 100 U.S. dollars for each clinic visit during the study.
The report, from the medical news publication Stat, cited a video made by a researcher at the University of Chicago who is helping conduct a trial of Gilead’s drug Remdesivir.
UPDATED:
Ads
Ads
Sponsored Links
The University of Chicago Medicine Hospital recruited a total of 125 people with COVID-19 into Gilead’s two Phase 3 clinical trials. Most of those people, 113 had severe disease. All of the patients have been treated with daily infusions of Remdesivir. The researcher, infectious disease professor Kathleen Mullane, said that most patients had been discharged from the hospital and only two had died.
Remdesivir is causing "rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week" in patients at a Chicago hospital
Stat News report: "The best news is that most of our patients have already been discharged, which is great. We've only had two patients perish. Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesn't have to be 10 days." said Professor Mullane. “It’s always hard,” she said, because the severe trial doesn’t include a placebo group for comparison. “But certainly when we start [the] drug, we see fever curves falling,” she said. “Fever is now not a requirement for people to go on trial, we do see when patients do come in with high fevers, they do [reduce] quite quickly. We have seen people come off ventilators a day after starting therapy. So, in that realm, overall our patients have done very well.”
What is REMDESIVIR?
It is also one of the 4 drugs being use under WHO Solidarity trials. Remdesivir is an antiviral medication; a nucleotide analog, specifically an adenosine analogue, which inserts into viral RNA chains, causing their premature termination. It is being studied during 2020 as a possible post-infection treatment for COVID-19 illness.
There’s only one drug right now that we think may have real efficacy,” Bruce Aylward of the World Health Organization said last month. “And that’s Remdesivir.”
Coronavirus patients around the world have been rushing to join Remdesivir studies that opened in hospitals in the last few weeks
Gilead says in a fact sheet about Remdesivir the drug Remdesivir was invented by Gilead building on more than a decade of our research. Over that time, our research
scientists have explored the compound for multiple potential uses to help address urgent and unmet medical needs
around the world, including Ebola, SARS, Marburg, MERS and most recently COVID-19. O ur antiviral expertise is the
result of more than 30 years of research and the investment of billions of dollars in research and development.
Gilead’s antiviral work reflects its commitment to collaborating with the global health community and advancing
potential treatments that may help in the global response to public health emergencies.
Remdesivir is an investigational new drug created by Gilead. The research that led to remdesivir began as early as 2009,
with research programs under way in hepatitis C (HCV) and respiratory syncytial virus (RSV). We continued to explore
various uses for remdesivir following its discovery, including antiviral profiling in 2013 and early 2014 that suggested the
potential for remdesivir to have broad spectrum antiviral activity. Gilead’s ground-breaking research has led to an expansive library of compounds invented by Gilead that includes remdesivir. This archive of molecules can be accessed and tested against new viruses as they emerge. Our chemists continually
work to invent new compounds, and Gilead has invested resources and time over decades so that even when a molecule
initially seems unpromising, it may yet one day save lives.
By working in collaboration with both academic institutions and U.S. government agencies, we have been able to bring
together disease experts to help expand knowledge of the antiviral profile of remdesivir against emerging viruses, including
Ebola, SARS, Marburg, and MERS through in vitro studies and in vivo studies in animal models. Testing of remdesivir against
the virus that causes COVID-19 is ongoing COVID-19
In January 2020, when a new pneumonia-like illness in China was identified as a coronavirus, Gilead moved quickly to determine whether remdesivir could play a role in responding to the growing public health threat that subsequently became known
as COVID-19. Gilead’s preclinical data suggested that testing remdesivir against COVID-19 should take place immediately. • Gilead’s team of virologists quickly generated the preclinical
data to characterize remdesivir’s activity against the new
COVID-19 virus and to determine the potential benefit of
further testing. • In January 2020, Gilead provided remdesivir to the China
CDC to test the compound against isolates of the virus that
causes COVID-19 through their independent antiviral assays.
Gilead provided remdesivir to U.S. academic institutions in
February 2020 for similar testing. Results are expected soon. • In February 2020, Gilead began supporting multiple
clinical trials to evaluate the safety and efficacy of remdesivir
as a potential treatment for COVID-19. • Gilead donated study drug and provided scientific input
for two clinical trials coordinated by the China-Japan
Friendship Hospital in China, which began enrolling patients
in early to mid- February. • Gilead donated drugs and provided scientific input for a
NIAID-initiated global clinical trial of remdesivir in late February, including the first site to enroll patients in the United States. • In late February, Gilead initiated its own two Phase 3
studies of remdesivir, which will enroll patients in countries
globally with high numbers of diagnosed COVID-19 cases.
These studies began enrolling patients in March 2020 and
will evaluate two dosing durations of remdesivir. • Gilead has provided input on the design of both WHO’s global
Solidarity trial and the INSERM-sponsored DisCoVeRy trial in
Europe. These trials have already initiated and will expand
to additional countries over the coming months. Gilead has
committed to providing remdesivir to support these studies,
which will be conducted in more than 70 countries worldwide. • In anticipation of potential future needs, we have accelerated
manufacturing timelines to increase our available supply as
rapidly as possible. We are doing this before knowing whether
remdesivir will be determined to be safe and effective to treat
patients with COVID-19
Ayun sa Japan Industry Ministry at sa isang UK Doctor na nagtratrabaho sa NHS, mas effective diumano ang Dishwashing Soap bilang panghugas ng mga gamit at kamay laban sa Corona Virus 2019. Ito ang itsura ng Novel Corona Virus 2019. Ang nasa loob ng bilog na yan ang ang virus na natatakpan ng tinatawag nilang lipid layer o fatty shell. Para tuluyang mapuksa ang virus, kailangan mo ng sabon na bilang degreaser na siyang bubuwag ng bilog na shell o nucleus na iyan. Panoorin ang video sa ibaba para mas maintindihan. Naalala mo ang dishwashing soap na kayang tanggalin ang mantika at sebo? Ganyan na ganyan ang Corona Virus, parang sebo na kapag nahugasan ng sabon ng atleast 20seconds ay namamatay. How soap kills the corona virus? Watch this.
Ads
Ads
Sponsored Links
Ayun pa sa report, ang dishwashing soap ay epektibo sa paglilinis at pagdidisinfect ng novel corona virus sa ulat ng Japan's industry ministry nitong Miyerkules.
Ang dishwashing soap ay magagamit na alternabo sa mga alcohol-based disinfectants kagaya ng hand sanitizers at alcohol na sobrang salat sa stocks at paubusan ang suplay.
Ayun pa sa mga eksperto sa Japan, may tatlong compounds na lumalaban sa coronavirus at ito ay ang surfactants, karaniwang ginagamit sa mga sabon at cleaners, hypochlorous acid water, at quaternary ammonium salts. Samantala ito naman ang tinatagal ng COVID19 sa hangin, sa copper, sa mga hawakan ng pintuan at switches ng ilaw, sa cardboard, plastic at glass.
Just a quick reminder COVID-19 is enclosed (the skin if you like) is fatty tissue, so soap and water breaks that down, also dish washing liquid, so use soap for long enough to cut down on the risk, no quick finger waggling under water
Dishwashing soap contains a degreaser. The virus is encased in a fatty shell. Degreaser is exactly what you need. If you're struggling to buy hand-wash, you can still use soap, shower gels, even dishwashing liquid. Basically, any soap that will destroy the lipid layer around the virus. You need to dissolve the oily coating on the virus to kill the nucleus. Dishwashing soap is perfect. Dishwashing liquid kills germs too. Plain old bar soap is fine as well. Any kind of soap will break down the outside surface of the virus and kill it. The reason soap work is because this particular virus is sitting inside a fatty envelope and so soaps that are designed to break up fat will make it fall apart. I recently heard a doctor or research head speaking on the virus and he said that every coronavirus has a lipid coating that is vital to its life. Plain soap breaks up lipids. Dishwashing liquid best of all. Strip the virus of its coating of fat, say bye-bye virus.
A report from MarketWatch says this: Soap dissolves the fat membrane, and the virus falls apart like a house of cards and “dies,” or rather, it becomes inactive as viruses aren’t really alive. Viruses can be active outside the body for hours, even days.
Disinfectants or liquids, wipes, gels and creams containing alcohol (and soap) have a similar effect but are not as good as regular soap. Apart from alcohol and soap, antibacterial agents in those products don’t affect the virus structure much. Consequently, many antibacterial products are basically just an expensive version of soap in how they act on viruses. Soap is the best, but alcohol wipes are good when soap is not practical or handy, for example in office reception areas
Soapy water is totally different. The soap contains fat-like substances known as amphiphiles, some structurally similar to the lipids in the virus membrane. The soap molecules “compete” with the lipids in the virus membrane. That is more or less how soap also removes normal dirt of the skin (see graphic at the top of this article).
The soap molecules also compete with a lot of other non-covalent bonds that help the proteins, RNA and lipids to stick together. The soap is effectively “dissolving” the glue that holds the virus together. Add to that all the water.
The soap also outcompetes the interactions between the virus and the skin surface. Soon the virus gets detached and falls apart like a house of cards due to the combined action of the soap and water. Boom, the virus is gone!
The skin is rough and wrinkly, which is why you need a fair amount of rubbing and soaking to ensure the soap reaches every nook and cranny on the skin surface that could be hiding active viruses.
Alcohol-based products include all “disinfectants” and “antibacterial” products that contain a high share of alcohol solution, typically 60%-80% ethanol, sometimes with a bit of isopropanol, water and a bit of soap.
Ethanol and other types of alcohol do not only readily form hydrogen bonds with the virus material but, as a solvent, are more lipophilic than water. Hence, alcohol does dissolve the lipid membrane and disrupt other supramolecular interactions in the virus.
However, you need a fairly high concentration (maybe 60%-plus) of the alcohol to get a rapid dissolution of the virus. Vodka or whiskey (usually 40% ethanol) won’t dissolve the virus as quickly. Overall, alcohol is not as good as soap at this task.
Nearly all antibacterial products contain alcohol and some soap, and that does help kill viruses. But some also include “active” bacterial killing agents, such as triclosan. Those, however, do basically nothing to the virus.
Hand sanitizers with at least 60% alcohol and 20 seconds washing with soap are effective in killing the virus
Ngayong ipinapatupad ang Enhanced Community Quarantine ay maaring may mga pagkakataong kailangang-kailangang lumabas ng bahay upang magtrabaho o bumili ng basic necessities. Narito ang mga tips at infographics na inihanda ng DOH o Department of Health upang maiwasang makapasok ang #COVID19 o Corona Virus sa bahay.
Ads
Ads
Sponsored Links
Hindi man kayang magdisinfect ng buong bahay pero kung may wastong pag-iingat ay mababawasan ang panganib ng pagpasok ng COVID19 sa ating pamamahay na siyang magiging sanhi ng pagkainfect ng ating buong pamilya lalo na ang mga vulnerables o may mga existing condition at mga mahihina ang immune system.
Maliban kung may emergency o higit na pangangailangan, ay huwag ng umalis ng bahay. Kung kinakailangang umalis ng bahay, magdala ng alcohol o hand sanitizer. Huwag din hawakan ang mukha habang nasa labas ng bahay. Pag nakauwi na, mag-spray ng alcohol sa swelas, at hubarin ang sapatos bago pumasok sa bahay. Ilagay ang ginamit na sapatos sa labas ng bahay o malapit sa pintuan.
Hubarin ang iyong damit at ilagay sa hiwalay na laundry bag. Labhan ito gamit ang tubig, detergent at konting bleach sa madaling panahon. (Sa amin, binababad namin sa chlorinated water o zonrox or chlorox at tubig.)
Research Institute of Tropical Medicine and the Department of Health Formulation
ZONROX or CHLOROX
9 glasses of clean water + 1 glass of Zonrox = disinfect surfaces
Get 1 glass from the above mixture then add 9 glasses of water = disinfect your hands
POWDERED CHLORINE
1 tablespoon of chlorine powder + 2 liters water = disinfect surfaces
1 tablespoon of chlorine powder + 20 liters water = disinfect your hands
Suggestion namin sa mga pumapasok araw-araw o lumalabas ng bahay.
1. Iwasan na muna ang bumili ng mga kung ano anong foods at kumain sa labas. Hindi natin alam baka infected na ang nagprepare or nagseserve.
2. Maligo ng Chlorinated Water bago pumasok ng bahay. Ilang patak lang ng chlorine o zonrox o chlorox sa isang timba na water.
3. Maglagay ng babaran ng sapatos na Chlorinated sa labas ng bahay. Ang mga sapatos nakakaapak yan ng mga dura at kung ano ano pa.
4. Ibabad ang mga damit na sinuot paglabas ng bahay sa timba o palanggana na may Chlorine o Bleach.
ARAW-ARAW po yan habang nabiyahe at expose sa labas at madaming tao.
The American Chemistry Council's (ACC) Center for Biocide Chemistries (CBC) has compiled a list of products that have been pre-approved by the U.S. Environmental Protection Agency
(EPA) for use against emerging enveloped viral pathogens and can be used during the 2019 novel coronavirus (COVID-19) outbreak.
This product list is not exhaustive but can be used by
business owners, health professionals, and the public to identify products suitable for use during the COVID-19.
The information in this document is being provided as a public service. Persons receiving this information must make their own determination as to a product's suitability prior to use based on product
labeling.
Ads
This Novel Coronavirus (COVID-19)—Fighting Products are listed on American Chemistry website and are duly approved against emerging enveloped viral pathogens and can be used during the 2019 novel coronavirus (COVID-19) outbreak. We are getting the list from the Dept of Health of the list if there's any for products sold locally that can also help fight viruses.
Ads
Sponsored Links
Ready to Use or DILUTABLE Products Against COVID19. Here is the list:
Fabuloso Complete Disinfecting Wipes Colgate-Palmolive
Company
Germ Freak Bissell Homecare, Inc.
Handyclean™ Steridol Wipes Diamond Wipes International, Inc.
I7 DISINFECTANT WIPES Ecolab Inc/Kay Chemical Co.
INTERvention Farm Animal Care Disinfectant Cleaner &
Deodorizer Ready to Use Wipes
LCP BROAD SPECTRUM GERMICIDAL & DISINFECTANT WIPES LOR
Cleaner Products
Monk Disinfectant Wipes Dreumex USA, Inc.
MULTI-PURPOSE DISINFECTING WIPES Ecolab Inc
NASSCO PRO SERIES 88 BROAD SPECTRUM GERMICIDAL &
DISINFECTANT WIPES
NCLwipes Disinfectant Wipes Lemon Fresh National Chemical
Laboratories, Inc.
NCLwipes Disinfectant Wipes Waterfall Fresh National
Chemical Laboratories, Inc.
Optim 1 Wipes SciCan Ltd.
Optim 33 Tb Wipes SciCan Ltd.
Oxivir 1 Wipes Diversey, Inc.
OXIVIR™ WIPES Diversey, Inc.
Pathos II Disinfectant Wipes Share Corporation
Peroxigard Wipes One-Step Disinfectant Cleaner and
Deodorizer
PREempt Wipes Virox Technologies, Inc.
PURELL Foodservice Surface Sanitizing Wipes GOJO Industries,
Inc.
PURELL Professional Surface Disinfectant Wipes GOJO
Industries, Inc.
Rejuvenate Ready To Use Wipes One-Step Disinfectant Cleaner
REScue Wipes One-Step Disinfectant Cleaner & Deodorizer
Virox Technologies, Inc.
Sani-Cloth Prime Germicidal Disposable Wipe Professional
Disposables International,
SCRUBS® MEDAPHENE® Plus Disinfecting Wipes ITW Pro Brands
SONO Disinfecting Wipes Advanced Ultrasound Solutions, Inc.
SONO Ultrasound Wipes Advanced Ultrasound Solutions, Inc.
Spec4 Disinfectant Wipes Total Solutions
SSS TRIPLE S DISINFECTANT WIPES Triple S
TouchPoint Plus Disinfectant Wipes Innocore Sales &
Marketing
Wipes Plus Disinfecting Wipes 1 Progressive Products, LLC.
As a public service, US CBC is maintaining this list of antimicrobials that have proven to be effective against stronger pathogens, such as norovirus
or ebola. By publishing and maintaining this open list, CBC relieves federal, state, and local health officials’ resources in order to focus on other
aspects of the important effort to limit the spread of this new disease. Listing is voluntary and compliance with EPA’s “emerging viral pathogen”
guidance for antimicrobial products is verified by CBC. CBC will be working with federal and state officials to disseminate the list and make it
accessible to all those who need to be in the know.
/cdn.vox-cdn.com/uploads/chorus_asset/file/19854782/soapdemolish.gif)
